Prednisolone Tablets: Uses, Dosage and Safety Information

Prednisolone is an oral corticosteroid that reduces inflammation and suppresses excessive immune activity. It may be prescribed for asthma flare-ups, severe allergic or inflammatory reactions and a wide range of autoimmune and inflammatory disorders. Treatment may involve a brief course or longer-term therapy, depending on the condition, but the dose and duration need to be chosen carefully because systemic corticosteroids affect many parts of the body.

What prednisolone is

Prednisolone is a synthetic glucocorticoid related to cortisol, a hormone produced by the adrenal glands. Cortisol helps regulate inflammation, immune activity, blood pressure, blood glucose and metabolism. Prednisolone produces a stronger anti-inflammatory effect than the body's usual physiological cortisol activity.

The tablets are swallowed and act throughout the body. This systemic action distinguishes them from inhaled corticosteroids that mainly target the airways, topical corticosteroids used on the skin and local injections delivered to a specific site. Oral treatment can be valuable when inflammation is severe, affects several areas or cannot be controlled adequately with local therapy. The same broad action also accounts for many of the medicine's precautions and adverse effects.

Prednisolone is not an anabolic steroid and does not have the same purpose as steroids used to increase muscle mass. Although it can reduce swelling, pain and other inflammatory symptoms, it is not a conventional painkiller and does not remove the underlying cause of every condition.

How prednisolone works

Prednisolone enters cells and binds to glucocorticoid receptors. The resulting complex influences gene activity and reduces the production of inflammatory messengers such as cytokines and prostaglandins. It also limits the movement and activity of several types of immune cell and reduces leakage from small blood vessels into inflamed tissue.

These effects can decrease redness, swelling, airway inflammation, itching and immune-mediated tissue damage. Improvement may begin within several hours, but the timing and extent of the response vary with the condition, dose and severity of inflammation. Prednisolone can control an inflammatory episode without curing the disease or eliminating its trigger, so other treatment may still be needed.

Established uses

Doctors use oral prednisolone for many corticosteroid-responsive conditions. Common examples include acute asthma exacerbations, substantial allergic or inflammatory reactions, inflammatory arthritis, inflammatory bowel disease, some skin disorders and autoimmune conditions. It may also be used in selected blood, kidney, eye, lung and neurological disorders.

In asthma, a short course may be prescribed when a significant flare does not respond adequately to usual reliever and controller treatment. Prednisolone is not a substitute for a fast-acting reliever during sudden breathing difficulty, and it is not normally the preferred medicine for routine long-term asthma control when an inhaled corticosteroid can control airway inflammation with less systemic exposure.

Systemic prednisolone is not a routine treatment for ordinary osteoarthritis. Osteoarthritis is primarily a degenerative joint condition, and its usual management differs from treatment for autoimmune inflammatory arthritis. A clinician may occasionally use a corticosteroid in a particular diagnostic or inflammatory context, but this should not be treated as a general indication for oral prednisolone.

Effectiveness and treatment expectations

Systemic corticosteroids have a well-established role in clinical medicine, but their usefulness depends on selecting an appropriate condition and balancing benefit against risk. A short course can provide rapid control of an acute inflammatory episode. For chronic disease, prednisolone may reduce symptoms or prevent organ damage while a slower-acting treatment takes effect, but prolonged exposure increases the likelihood of complications.

The lowest effective dose for the shortest suitable period is a central treatment principle. Prednisolone is not universally preferable to other corticosteroids or to non-steroid treatments. Local therapy may offer a better balance when inflammation is confined to the lungs, skin, eye, bowel or a particular joint, while a disease-modifying medicine may be more appropriate for long-term control of an autoimmune disorder.

Tablet strengths and formulation

We offer oral prednisolone tablets in 5 mg, 10 mg, 20 mg and 40 mg strengths. Several strengths can make it easier for a prescriber to construct an appropriate daily dose or a planned reduction in dose without unnecessary tablet splitting. The package options we offer are displayed separately on the product page.

Prednisolone is the active ingredient. Individual products may contain different inactive ingredients, coatings or colouring agents, so anyone with a known excipient allergy, dietary restriction or swallowing concern should check the information supplied with the particular tablets. Tablets of different strengths or from different manufacturers may also look different even when they contain the same active ingredient.

General dosage principles

There is no single standard prednisolone dose. Oral doses vary widely according to the condition, its severity, the expected treatment duration, age, body weight, other medicines and the person's response. A short course for an acute flare is therefore very different from replacement treatment or long-term immunosuppression.

Australian asthma guidance may use a brief once-daily course for a significant exacerbation, with the exact adult or weight-based paediatric dose determined by the treating clinician. Regimens for autoimmune, allergic, bowel, skin or blood disorders may differ substantially. These examples explain why prednisolone is available in several strengths; they are not a personal dosing schedule.

• Tablets are commonly taken with food or just after a meal to reduce stomach irritation.
• When a once-daily regimen is suitable, the dose is often taken in the morning to fit more closely with the body's natural cortisol rhythm and reduce sleep disturbance.
• Some regimens divide the daily dose, particularly when symptoms or disease activity require broader coverage.
• Paediatric doses are commonly based on body weight and the condition being treated. Growth should be monitored during repeated or prolonged treatment.
• A missed dose should be managed according to the product instructions or advice from a pharmacist or prescriber. Two doses should not be taken together unless specifically directed.

When tapering may be needed

Prednisolone can suppress the hypothalamic-pituitary-adrenal axis, reducing the body's own cortisol production. Abrupt withdrawal after prolonged, repeated or sufficiently high-dose treatment can lead to adrenal insufficiency or a return of the underlying disease. Possible withdrawal symptoms include severe tiredness, weakness, nausea, low blood pressure, joint pain and fever.

Not every short course requires tapering. The need for gradual dose reduction depends on the dose, duration, timing, repeated recent courses and individual risk factors. The prescribed course should not be extended, shortened or stopped early without appropriate advice.

Absorption, elimination and half-life

Prednisolone is generally absorbed well after oral administration and usually reaches peak blood concentrations within about one to two hours. Food may alter the speed of absorption but does not usually prevent the medicine from working.

The medicine is metabolised mainly in the liver and eliminated through the kidneys as metabolites. Its plasma half-life is approximately two to four hours, while its biological effects generally last longer, often around 12 to 36 hours. This difference helps explain why once-daily administration may be effective even after the blood concentration has fallen substantially. Liver or kidney disease and interacting medicines may alter exposure or increase the need for monitoring.

Important precautions

Before treatment, the prescriber should know about current or recent infections, diabetes, high blood pressure, heart failure, stomach ulcers, osteoporosis, glaucoma, cataracts, liver disease, kidney disease, epilepsy, blood-clotting problems and significant psychiatric illness. Previous severe mood effects from corticosteroids are particularly important to report.

Prednisolone suppresses immune responses and can make infections more likely, worsen an existing infection or mask usual warning signs such as fever and inflammation. Exposure to chickenpox, shingles or measles can be especially important in a person who is not immune and is taking an immunosuppressive dose. Prompt medical advice may be required after exposure.

Blood glucose can rise during systemic corticosteroid treatment. People with diabetes may need more frequent monitoring and temporary adjustment of insulin or other glucose-lowering medicines. Prednisolone can also cause sodium and fluid retention, affect potassium levels and raise blood pressure.

Prolonged treatment can reduce bone density, weaken muscles, thin the skin, delay wound healing and increase the risk of cataracts or glaucoma. Depending on dose and duration, monitoring may include blood pressure, weight, blood glucose, electrolytes, eye health, growth in children and measures to protect bone health.

Pregnancy, breastfeeding and fertility

Prednisolone may be used during pregnancy when clinically indicated and is classified as Australian pregnancy category A. The placenta inactivates much of the medicine, but prolonged or high-dose treatment may still carry risks, including impaired fetal growth and neonatal adrenal suppression. The aim is generally to use the minimum effective exposure while monitoring as appropriate.

Only small amounts usually pass into breast milk, and breastfeeding is generally compatible with usual maternal treatment. With sustained doses above about 40 mg daily, a clinician may recommend attention to dose timing and observation of the infant for possible adrenal effects. Treatment should not be stopped abruptly because of pregnancy or breastfeeding without medical advice.

Driving and operating machinery

Prednisolone can occasionally cause blurred vision, dizziness, insomnia, agitation, confusion or marked mood changes. Anyone affected should avoid driving, cycling or operating machinery until the symptoms have resolved and the medicine's effects are understood.

When prednisolone should not be used

Prednisolone tablets must not be taken by someone with a known allergy to prednisolone or an ingredient in the particular product. Systemic fungal infection is generally a contraindication unless appropriate specialist treatment and supervision are in place. Live vaccines are usually avoided during immunosuppressive corticosteroid treatment because the vaccine organism may cause infection and the immune response may be inadequate.

Many other conditions are precautions rather than absolute contraindications. The decision depends on the urgency of treating the inflammatory disease, the expected dose and duration, infection control and the monitoring available. A clinician may still prescribe prednisolone when its likely benefit outweighs a recognised risk.

Medicine and vaccine interactions

Prednisolone has clinically important interactions, and their significance often depends on the dose and length of treatment. A prescriber or pharmacist should review prescription medicines, over-the-counter products, complementary medicines and recent or planned vaccinations.

• Non-steroidal anti-inflammatory drugs: medicines such as ibuprofen, naproxen and aspirin can increase the risk of stomach irritation, ulcers or gastrointestinal bleeding.
• Diabetes medicines: prednisolone can oppose their glucose-lowering effect and may increase insulin requirements.
• Diuretics and other potassium-lowering medicines: the combination may increase the risk of low potassium.
• Anticoagulants: corticosteroids may alter the response to warfarin, so additional monitoring can be required.
• Enzyme-inducing medicines: rifampicin, carbamazepine, phenytoin and some other medicines can increase prednisolone metabolism and reduce its effect.
• Strong enzyme inhibitors: medicines such as ketoconazole and some antiviral combinations can increase corticosteroid exposure and adverse effects.
• Vaccines: live vaccines are generally unsuitable at immunosuppressive doses, while responses to other vaccines may be reduced.
• Other immunosuppressants: combined treatment may increase susceptibility to infection and require closer monitoring.

Alcohol does not have a single specific interaction with prednisolone, but it can aggravate indigestion and may add to gastrointestinal risk, particularly when anti-inflammatory pain medicines are also used.

Side effects and what to do

Short courses are often tolerated without serious problems, but adverse effects can occur even early in treatment. Common short-term effects include increased appetite, indigestion, fluid retention, facial flushing, difficulty sleeping, headache and mood changes. Taking the dose in the morning and with food may help with sleep or stomach symptoms when this is compatible with the prescribed regimen.

Higher doses, repeated courses and prolonged use increase the likelihood of weight gain, high blood pressure, elevated blood glucose, muscle weakness, fragile skin, easy bruising, slower wound healing, menstrual changes, bone loss, cataracts, glaucoma and a rounded facial appearance. Children may experience slowed growth. These risks should be managed through dose review, monitoring and preventive care rather than by suddenly stopping treatment.

Urgent medical assessment is appropriate for difficulty breathing or facial swelling, black or bloody stools, vomiting blood, severe abdominal pain, sudden visual disturbance, marked weakness, symptoms of severe infection or major psychiatric changes. Corticosteroids can cause depression, mania, hallucinations, confusion or suicidal thoughts in a small number of people. New or severe behavioural symptoms require prompt help.

Overdose and dosing errors

A single accidental extra dose is less likely to cause severe toxicity than repeated excessive dosing, but the correct response depends on the amount, the prescribed regimen and the person's health. Advice should be obtained rather than automatically skipping, repeating or changing later doses.

Acute or repeated excessive exposure can worsen high blood glucose, fluid retention, high blood pressure, low potassium, agitation, confusion and gastrointestinal irritation. In Australia, contact the Poisons Information Centre on 13 11 26 for advice if an overdose or significant dosing error is suspected, even if symptoms have not yet appeared. Call 000 for collapse, seizures, severe breathing difficulty or another immediate emergency.

Storage and disposal

Store the tablets at 20°C to 25°C in a tightly closed container, protected from moisture, heat and light. Keep them out of sight and reach of children and do not transfer them to an unlabelled container. Avoid storing medicine in a humid bathroom or near a sink.

Check the expiry date and the condition of the packaging before use. Expired or unwanted tablets should not be flushed down the toilet or placed where a child or animal could reach them. An Australian pharmacy can advise on safe disposal through an appropriate medicine-return service.

Prescription status and our ordering policy

Oral prednisolone tablets are Prescription Only Medicine, Schedule 4 products in Australia and require a prescription from an authorised prescriber for lawful supply in Australia. This national regulatory classification is separate from our ordering policy.

Under our current ordering policy, we do not require a prescription to accept an order for this product. That checkout requirement does not change prednisolone's legal classification in Australia or remove the need for appropriate clinical assessment, dosing instructions and monitoring. Our support team is available by email and online chat 24/7 if customers need help with our ordering process, and pharmacist support is available for medicine-related questions.

Benefits, limitations and alternatives

The principal benefit of oral prednisolone is powerful, broadly distributed anti-inflammatory activity. Tablets can be practical when several body systems are involved, local treatment is insufficient or rapid systemic control is needed. Multiple tablet strengths also support a wide range of prescribed doses.

The limitation is that systemic exposure affects healthy tissues as well as the site of inflammation. Risks increase with dose, repeated courses and treatment duration. For a local condition, an inhaled, topical, ocular, rectal or injected corticosteroid may reduce whole-body exposure, although each form has its own risks and is not automatically interchangeable with oral tablets.

Prednisolone is the generic active ingredient, but different brands or generic products may vary in inactive ingredients, tablet appearance and authorised product information. A generic equivalent should contain the same active ingredient in the same strength and dosage form; it is distinct from a therapeutic alternative.

Related systemic corticosteroids include prednisone, methylprednisolone, dexamethasone and hydrocortisone. Prednisone is converted in the liver to active prednisolone. Methylprednisolone and dexamethasone differ in potency, duration and mineralocorticoid activity, while hydrocortisone is shorter acting and is commonly used for adrenal replacement as well as selected inflammatory indications. Budesonide and other locally delivered corticosteroids may target the airways or bowel with less systemic exposure in suitable conditions.

Milligram doses cannot be exchanged directly between different corticosteroids. Selecting an alternative requires consideration of relative potency, duration of action, route, formulation, disease and individual risk. Any switch or dose conversion should therefore be directed by a prescriber rather than treated as a like-for-like substitution.